REG - HSBC Global Funds - Shareholder Notice

HSBC HoldingsAnnouncement

14/04/2025 16:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250414:nRSN9551Ea&default-theme=true

RNS Number : 9551E  HSBC Global Funds ICAV  14 April 2025

This letter is important and requires your immediate attention. If you are in
doubt as to the action you should take you should seek advice from your
stockbroker, bank manager, solicitor, accountant or other independent
financial adviser.

 

If you have sold or transferred all of your interests in the Sub-Fund (as
defined below), please pass this letter at once to the purchaser or transferee
or to the stockbroker, bank or other agent through whom the sale or transfer
was effected for transmission to the purchaser or transferee as soon as
possible.

 

This letter has not been reviewed by the Central Bank of Ireland (the "Central
Bank") and it is possible that changes may be necessary to meet the Central
Bank's requirements. The board of directors of the ICAV (the "Directors")
accepts responsibility for the information contained in this letter. To the
best of the knowledge and belief of the Directors (who have taken all
reasonable care to ensure that such is the case) the information contained in
this document is in accordance with the facts and does not omit anything
likely to affect the import of such information.

 

Capitalised terms used in this letter and not defined shall having the meaning
given to those terms in the prospectus for the ICAV dated 17 November 2023, as
may be amended from time to time (the "Prospectus").

 

 

14 April 2025

Dear Shareholder,

The purpose of this letter is to notify you of a proposed amendment to the
HSBC Global Funds ICAV - Global Corporate Bond UCITS ETF (the "Sub-Fund").

Asset Backed Securities ("ABS") and Mortgage Backed Securities ("MBS")
Amendment

Supplement Wording Amendment

The supplement for the Sub-Fund refers to the ability to invest in ABS and
MBS. However, the Sub-Fund does not invest in ABS or MBS and this provision is
not required. It is therefore proposed to remove the disclosure from the
supplement as demonstrated below:

 

 Existing Wording                                                               Proposed New Wording
 The Sub-Fund may invest in corporate Investment Grade bonds, corporate         The Sub-Fund may invest in corporate Investment Grade bonds, corporate
 emerging market bonds, Asset Backed Securities ("ABS") and Mortgage Backed     emerging market bonds and other bonds all of which are Index constituents.
 Securities ("MBS") all of which are Index constituents and may be callable."

 

 

Effective Date

Subject to the approval of the Central Bank, it is proposed that the amendment
to the supplement will take effect on or around 28 April 2025.

 

 

You do not need to take any action on receipt of this letter. Should you have
any questions or concerns in relation to the above, please contact
etfandindexingsales@hsbc.com (mailto:etfandindexingsales@hsbc.com) , the
client service team within HSBC Investment Funds (Luxembourg) S.A., the ICAV's
appointed Management Company in Luxembourg, or the Administrator, HSBC
Securities Services (Ireland) DAC. Additional information, including the Key
Investor Information Documents, PRIIPs KIDs, Prospectus, Supplement and most
recent financial statements are available by choosing your local website at
www.global.assetmanagement.hsbc.com
(http://www.global.assetmanagement.hsbc.com) or from the registered office.

 

 

 

 

 

 

Yours sincerely,

 

 

 

Director

For and on behalf of

HSBC Global Funds ICAV

 

 

 

 

Further Information

 

 HSBC Global Funds ICAV  3 Dublin Landings, North Wall Quay, Dublin 1 Ireland  +353 1 635 6000*
 J&E Davy (Sponsor)                                                            +353 1 679 6363*

 Brian Garrahy

 

 

* Calls may be recorded

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCZZLFFEZLFBBZ